BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

252 related articles for article (PubMed ID: 24397991)

  • 1. A meta-analysis of the risk of total cardiovascular events of isosmolar iodixanol compared with low-osmolar contrast media.
    Zhang BC; Wu Q; Wang C; Li DY; Wang ZR
    J Cardiol; 2014 Apr; 63(4):260-8. PubMed ID: 24397991
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The relative renal safety of iodixanol compared with low-osmolar contrast media: a meta-analysis of randomized controlled trials.
    Reed M; Meier P; Tamhane UU; Welch KB; Moscucci M; Gurm HS
    JACC Cardiovasc Interv; 2009 Jul; 2(7):645-54. PubMed ID: 19628188
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nephrotoxicity of iso-osmolar iodixanol compared with nonionic low-osmolar contrast media: meta-analysis of randomized controlled trials.
    Heinrich MC; Häberle L; Müller V; Bautz W; Uder M
    Radiology; 2009 Jan; 250(1):68-86. PubMed ID: 19092091
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Contrast-induced nephropathy in patients with diabetes mellitus between iso- and low-osmolar contrast media: A meta-analysis of full-text prospective, randomized controlled trials.
    Han XF; Zhang XX; Liu KM; Tan H; Zhang Q
    PLoS One; 2018; 13(3):e0194330. PubMed ID: 29558481
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Renal failure in 57 925 patients undergoing coronary procedures using iso-osmolar or low-osmolar contrast media.
    Liss P; Persson PB; Hansell P; Lagerqvist B
    Kidney Int; 2006 Nov; 70(10):1811-7. PubMed ID: 17003814
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cardiac events after low osmolar ionic or isosmolar nonionic contrast media utilization in the current era of coronary angioplasty.
    Le Feuvre C; Batisse A; Collet JP; Batisse JP; Choussat R; Beygui F; Helft G; Montalescot G; Metzger JP
    Catheter Cardiovasc Interv; 2006 Jun; 67(6):852-8. PubMed ID: 16649230
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Renal toxicity evaluation and comparison between visipaque (iodixanol) and hexabrix (ioxaglate) in patients with renal insufficiency undergoing coronary angiography: the RECOVER study: a randomized controlled trial.
    Jo SH; Youn TJ; Koo BK; Park JS; Kang HJ; Cho YS; Chung WY; Joo GW; Chae IH; Choi DJ; Oh BH; Lee MM; Park YB; Kim HS
    J Am Coll Cardiol; 2006 Sep; 48(5):924-30. PubMed ID: 16949481
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Iodixanol versus low-osmolar contrast media for prevention of contrast induced nephropathy: meta-analysis of randomized, controlled trials.
    From AM; Al Badarin FJ; McDonald FS; Bartholmai BJ; Cha SS; Rihal CS
    Circ Cardiovasc Interv; 2010 Aug; 3(4):351-8. PubMed ID: 20647563
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A meta-analysis of the renal safety of isosmolar iodixanol compared with low-osmolar contrast media.
    McCullough PA; Bertrand ME; Brinker JA; Stacul F
    J Am Coll Cardiol; 2006 Aug; 48(4):692-9. PubMed ID: 16904536
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A prospective, double-blind, randomized, controlled trial on the efficacy and cardiorenal safety of iodixanol vs. iopromide in patients with chronic kidney disease undergoing coronary angiography with or without percutaneous coronary intervention.
    Nie B; Cheng WJ; Li YF; Cao Z; Yang Q; Zhao YX; Guo YH; Zhou YJ
    Catheter Cardiovasc Interv; 2008 Dec; 72(7):958-65. PubMed ID: 19021282
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The relative renal safety of iodixanol and low-osmolar contrast media in patients undergoing percutaneous coronary intervention. Insights from Blue Cross Blue Shield of Michigan Cardiovascular Consortium (BMC2).
    Reed MC; Moscucci M; Smith DE; Share D; LaLonde T; Mahmood SA; D'Haem C; McNamara R; Greenbaum A; Gurm HS
    J Invasive Cardiol; 2010 Oct; 22(10):467-72. PubMed ID: 20944185
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nephrotoxic effects in high-risk patients undergoing angiography.
    Aspelin P; Aubry P; Fransson SG; Strasser R; Willenbrock R; Berg KJ;
    N Engl J Med; 2003 Feb; 348(6):491-9. PubMed ID: 12571256
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative Effect of Contrast Media Type on the Incidence of Contrast-Induced Nephropathy: A Systematic Review and Meta-analysis.
    Eng J; Wilson RF; Subramaniam RM; Zhang A; Suarez-Cuervo C; Turban S; Choi MJ; Sherrod C; Hutfless S; Iyoha EE; Bass EB
    Ann Intern Med; 2016 Mar; 164(6):417-24. PubMed ID: 26830055
    [TBL] [Abstract][Full Text] [Related]  

  • 14. One-year results of the ICON (Ionic versus non-ionic Contrast to Obviate worsening Nephropathy after angioplasty in chronic renal failure patients) Study.
    Giustino G; Baber U; Mastoris I; Vlachojannis GJ; Yu J; Teirstein PS; Downey WE; Batchelor WB; Casterella PJ; Nikolsky E; Wong SC; Theodoropoulos KN; Dangas GD; Mehran R
    Catheter Cardiovasc Interv; 2016 Mar; 87(4):703-9. PubMed ID: 26481591
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Influence of a nonionic, iso-osmolar contrast medium (iodixanol) versus an ionic, low-osmolar contrast medium (ioxaglate) on major adverse cardiac events in patients undergoing percutaneous transluminal coronary angioplasty: A multicenter, randomized, double-blind study. Visipaque in Percutaneous Transluminal Coronary Angioplasty [VIP] Trial Investigators.
    Bertrand ME; Esplugas E; Piessens J; Rasch W
    Circulation; 2000 Jan; 101(2):131-6. PubMed ID: 10637198
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ionic low-osmolar versus nonionic iso-osmolar contrast media to obviate worsening nephropathy after angioplasty in chronic renal failure patients: the ICON (Ionic versus non-ionic Contrast to Obviate worsening Nephropathy after angioplasty in chronic renal failure patients) study.
    Mehran R; Nikolsky E; Kirtane AJ; Caixeta A; Wong SC; Teirstein PS; Downey WE; Batchelor WB; Casterella PJ; Kim YH; Fahy M; Dangas GD
    JACC Cardiovasc Interv; 2009 May; 2(5):415-21. PubMed ID: 19463464
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Iodixanol compared to iohexol for contrast procedures: a case-matched retrospective cohort study.
    From AM; Bartholmai BJ; Williams AW; McDonald FS
    Acta Radiol; 2008 May; 49(4):409-14. PubMed ID: 18415784
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Iso-osmolar radio contrast iodixanol in patients with chronic kidney disease.
    Tadros GM; Malik JA; Manske CL; Kasiske BL; Dickinson SE; Herzog CA; Wilson RF; Das G; Panetta CJ
    J Invasive Cardiol; 2005 Apr; 17(4):211-5. PubMed ID: 15831975
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Randomized trial of contrast media utilization in high-risk PTCA: the COURT trial.
    Davidson CJ; Laskey WK; Hermiller JB; Harrison JK; Matthai W; Vlietstra RE; Brinker JA; Kereiakes DJ; Muhlestein JB; Lansky A; Popma JJ; Buchbinder M; Hirshfeld JW
    Circulation; 2000 May; 101(18):2172-7. PubMed ID: 10801758
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Iodixanol versus iopromide in patients with renal insufficiency undergoing coronary angiography with or without PCI.
    Zhang J; Jiang Y; Rui Q; Chen M; Zhang N; Yang H; Zhou Y
    Medicine (Baltimore); 2018 May; 97(18):e0617. PubMed ID: 29718868
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.